Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF

NCT04533022 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: C21

Sponsor

Vicore Pharma AB

Collaborators

[object Object]